These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

570 related items for PubMed ID: 22695538

  • 1. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
    Teunissen CE, Sombekke M, van Winsen L, Killestein J, Barkhof F, Polman CH, Dijkstra CD, Blankenstein MA, Pratico D.
    Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
    [Abstract] [Full Text] [Related]

  • 2. Brain lesion location and clinical status 20 years after a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis.
    Dalton CM, Bodini B, Samson RS, Battaglini M, Fisniku LK, Thompson AJ, Ciccarelli O, Miller DH, Chard DT.
    Mult Scler; 2012 Mar; 18(3):322-8. PubMed ID: 21878451
    [Abstract] [Full Text] [Related]

  • 3. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.
    Calabrese M, Rocca MA, Atzori M, Mattisi I, Favaretto A, Perini P, Gallo P, Filippi M.
    Ann Neurol; 2010 Mar; 67(3):376-83. PubMed ID: 20373349
    [Abstract] [Full Text] [Related]

  • 4. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis.
    Avsar T, Korkmaz D, Tütüncü M, Demirci NO, Saip S, Kamasak M, Siva A, Turanli ET.
    Mult Scler; 2012 Aug; 18(8):1081-91. PubMed ID: 22252467
    [Abstract] [Full Text] [Related]

  • 5. Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis.
    Di Perri C, Battaglini M, Stromillo ML, Bartolozzi ML, Guidi L, Federico A, De Stefano N.
    Arch Neurol; 2008 Feb; 65(2):236-43. PubMed ID: 18268194
    [Abstract] [Full Text] [Related]

  • 6. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
    Kragt JJ, Thompson AJ, Montalban X, Tintoré M, Río J, Polman CH, Uitdehaag BM.
    Neurology; 2008 Mar 25; 70(13 Pt 2):1084-91. PubMed ID: 18184917
    [Abstract] [Full Text] [Related]

  • 7. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP, Rovaris M, Comi G, Filippi M.
    Neurology; 2009 Nov 10; 73(19):1538-42. PubMed ID: 19794123
    [Abstract] [Full Text] [Related]

  • 8. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.
    Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg F, Hillert J, Piehl F, Olsson T.
    Mult Scler; 2011 Mar 10; 17(3):335-43. PubMed ID: 21135023
    [Abstract] [Full Text] [Related]

  • 9. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.
    Mult Scler; 2008 May 10; 14(4):479-84. PubMed ID: 18562504
    [Abstract] [Full Text] [Related]

  • 10. Lesion enhancement diminishes with time in primary progressive multiple sclerosis.
    Khaleeli Z, Ciccarelli O, Mizskiel K, Altmann D, Miller DH, Thompson AJ.
    Mult Scler; 2010 Mar 10; 16(3):317-24. PubMed ID: 20203148
    [Abstract] [Full Text] [Related]

  • 11. Alteration of prolyl oligopeptidase and activated α-2-macroglobulin in multiple sclerosis subtypes and in the clinically isolated syndrome.
    Tenorio-Laranga J, Peltonen I, Keskitalo S, Duran-Torres G, Natarajan R, Männistö PT, Nurmi A, Vartiainen N, Airas L, Elovaara I, García-Horsman JA.
    Biochem Pharmacol; 2013 Jun 15; 85(12):1783-94. PubMed ID: 23643808
    [Abstract] [Full Text] [Related]

  • 12. Deep grey matter T2 hypo-intensity in patients with paediatric multiple sclerosis.
    Ceccarelli A, Rocca MA, Perego E, Moiola L, Ghezzi A, Martinelli V, Comi G, Filippi M.
    Mult Scler; 2011 Jun 15; 17(6):702-7. PubMed ID: 21228024
    [Abstract] [Full Text] [Related]

  • 13. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G, COGIMUS Study Group.
    Mult Scler; 2009 Jul 15; 15(7):779-88. PubMed ID: 19542262
    [Abstract] [Full Text] [Related]

  • 14. Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study.
    Pulizzi A, Rovaris M, Judica E, Sormani MP, Martinelli V, Comi G, Filippi M.
    Arch Neurol; 2007 Aug 15; 64(8):1163-8. PubMed ID: 17698707
    [Abstract] [Full Text] [Related]

  • 15. Histogram analysis of diffusion measures in clinically isolated syndromes and relapsing-remitting multiple sclerosis.
    Yu CS, Lin FC, Liu Y, Duan Y, Lei H, Li KC.
    Eur J Radiol; 2008 Nov 15; 68(2):328-34. PubMed ID: 17928182
    [Abstract] [Full Text] [Related]

  • 16. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
    Teunissen CE, Iacobaeus E, Khademi M, Brundin L, Norgren N, Koel-Simmelink MJ, Schepens M, Bouwman F, Twaalfhoven HA, Blom HJ, Jakobs C, Dijkstra CD.
    Neurology; 2009 Apr 14; 72(15):1322-9. PubMed ID: 19365053
    [Abstract] [Full Text] [Related]

  • 17. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC.
    Neurology; 2009 Feb 24; 72(8):705-11. PubMed ID: 19073945
    [Abstract] [Full Text] [Related]

  • 18. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study.
    Rovaris M, Agosta F, Sormani MP, Inglese M, Martinelli V, Comi G, Filippi M.
    Brain; 2003 Oct 24; 126(Pt 10):2323-32. PubMed ID: 12937086
    [Abstract] [Full Text] [Related]

  • 19. The patients with clinically isolated syndrome and relapsing remitting multiple sclerosis show different levels of advanced protein oxidation products and total thiol content in plasma and CSF.
    Ljubisavljevic S, Stojanovic I, Vojinovic S, Stojanov D, Stojanovic S, Cvetkovic T, Savic D, Pavlovic D.
    Neurochem Int; 2013 Jun 24; 62(7):988-97. PubMed ID: 23500606
    [Abstract] [Full Text] [Related]

  • 20. Intrathecal IgM synthesis in pediatric MS is not a negative prognostic marker of disease progression: quantitative versus qualitative IgM analysis.
    Stauch C, Reiber H, Rauchenzauner M, Strasak A, Pohl D, Hanefeld F, Gärtner J, Rostásy KM.
    Mult Scler; 2011 Mar 24; 17(3):327-34. PubMed ID: 21123302
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.